Supreme Court backs generic drug maker in 'skinny label' patent case

By Allison Bell

News June 05, 2026 at 03:28 PM

Share & Print

What You Need To Know

Makers of brand name drugs typically have patents only for certain uses.
Generic drug makers using the skinny label strategy ask the FDA for approval for other, non-patented uses.
The Supreme Court ruled that Hikma efforts to sell its skinny label generic drug did not induce infringement on the use Amarin patented.

More From HR Executive

NOT FOR REPRINT

© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.